Evidence-based tools to support risk assessment and management planning
This tool estimates a patient's risk of developing melanoma over the next 3.5 years and is intended for those who have never been diagnosed previously with melanoma.
While New Zealand is a location option, this tool is based on Australian data.
This tool estimates a patient's risk of developing a first primary invasive melanoma during the rest of their life.
This tool is based on Australian data. New Zealand users are recommended to select Tasmania as the region as this most closely represents the New Zealand population.
This tool estimates a patient's risk of developing a keratinocyte cancer in the next three years. It is intended for those over 40 years of age.
This tool is based on Australian data.
This tool estimates a patient's risk of developing another primary melanoma over the 10 years following their most recent melanoma.
This tool is based on Australian data.
This tool estimates the risk that a patient's primary melanoma has spread to nearby lymph nodes.
This tool is based on Australian data.
This tool estimates risk of recurrence and overall survival for patients with high-risk localised melanoma. It is intended to support clinical decision-making around whether or not patients should have adjuvant immunotherapy.
This tool has been developed using data from over 10,000 patients.